-+ 0.00%
-+ 0.00%
-+ 0.00%

Crism Therapeutics Completes Site Initiation Visit for Lead NHS ChemoSeed Trial

MT Newswires·08/13/2026 04:31:26
Listen to the news
04:31 AM EDT, 08/13/2026 (MT Newswires) -- Crism Therapeutics (CRTX.L) said Thursday the site initiation visit at the lead NHS clinical trial site was completed. The chemotherapy-focused clinical-stage drug delivery company is working with the site and NHS trust to commence patient recruitment in the coming weeks for the phase 2 study, which will evaluate its proprietary implantable drug delivery technology, irinotecan ChemoSeed.